Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Summary

This phase II trial studies how well duvelisib on an intermittent (irregular) dosing schedule works in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving duvelisib on an intermittent schedule may result in similar effectiveness with less amount of severe side effects.

Timeline

Start

2020-05-13

Primary completion

2023-07-31

Completion

2026-10-26

Publications

• Shouse G, Chen L, Siddiqi T, Muir A, Brown JR, Spurgeon SE, Danilov AV. A phase II study of induction followed by intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Leuk Lymphoma. 2024 Oct;65(10):1516-1519. doi: 10.1080/10428194.2024.2361841. Epub 2024 Jun 5. No abstract available.

Drugs

Indications